Tumor-infiltrating lymphocytes: A new hope

Amod A Sarnaik; Patrick Hwu; James J Mulé; Shari Pilon-Thomas

doi:10.1016/j.ccell.2024.06.015

Tumor-infiltrating lymphocytes: A new hope

Cancer Cell. 2024 Aug 12;42(8):1315-1318. doi: 10.1016/j.ccell.2024.06.015. Epub 2024 Jul 18.

Authors

Amod A Sarnaik¹, Patrick Hwu², James J Mulé², Shari Pilon-Thomas³

Affiliations

¹ Immunology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA; Cutaneous Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. Electronic address: [email protected].
² Immunology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA; Cutaneous Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
³ Immunology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA; Center for Immunization and Infection Research in Cancer, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.

PMID: 39029463
DOI: 10.1016/j.ccell.2024.06.015

Abstract

Tumor-infiltrating lymphocytes (TILs) can be massively expanded from resected tumors and used as a cellular treatment for advanced malignancies. TILs require a preparative non-myeloablative chemotherapy followed by an abbreviated course of interleukin-2. Here, we review the historical development of TIL therapy and discuss potential solutions to ongoing roadblocks that may result in broader and improved efficacy for patients afflicted with treatment-refractory, advanced cancer.

Publication types

Review

MeSH terms

Animals
Humans
Immunotherapy, Adoptive / methods
Lymphocytes, Tumor-Infiltrating* / immunology
Neoplasms* / immunology
Neoplasms* / therapy